424 results on '"Kaitu'u-Lino, Tu'uhevaha"'
Search Results
2. Plasma metabolites are altered before and after diagnosis of preeclampsia or fetal growth restriction
3. Paternal Expressed Gene 10 (PEG10) is decreased in early-onset preeclampsia
4. Assessment of the tocolytic nifedipine in preclinical primary models of preterm birth
5. Plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant
6. Using the methylome to predict pre-eclampsia
7. Can single-cell and spatial omics unravel the pathophysiology of pre-eclampsia?
8. Cell surface associated protein mucin 15 (MUC15) is elevated in preeclampsia
9. Placental DAAM2 is unaltered in preeclampsia, but upregulated by treatment with proton pump inhibitors
10. The effect of metformin on cardiovascular markers in female mice consuming a high fat diet
11. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) is reduced with preeclampsia and small for gestational aged fetuses.
12. Exploring the Therapeutic Potential of C-Type Natriuretic Peptide for Preeclampsia.
13. LOX-1 expression is reduced in placenta from pregnancies complicated by preeclampsia and in hypoxic cytotrophoblast
14. Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia
15. Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction
16. DAAM2 is elevated in the circulation and placenta in pregnancies complicated by fetal growth restriction and is regulated by hypoxia
17. Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria
18. NR4A2 expression is not altered in placentas from cases of growth restriction or preeclampsia, but is reduced in hypoxic cytotrophoblast
19. Circulating trace elements for the prediction of preeclampsia and small for gestational age babies
20. Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia
21. Investigating ticagrelor in a preclinical pipeline as a novel therapeutic to prevent preterm birth.
22. Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome
23. EGFL7 gene expression is regulated by hypoxia in trophoblast and altered in the plasma of patients with early preeclampsia
24. Effect of sildenafil citrate on circulating levels of sFlt-1 in preeclampsia
25. MicroRNAs 363 and 149 are differentially expressed in the maternal circulation preceding a diagnosis of preeclampsia
26. Circulating mRNAs are differentially expressed in pregnancies with severe placental insufficiency and at high risk of stillbirth
27. Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction
28. Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin
29. EGFR (Epidermal Growth Factor Receptor) Signaling and the Mitochondria Regulate sFlt-1 (Soluble FMS-Like Tyrosine Kinase-1) Secretion
30. Loss of Akt increases soluble endoglin release from endothelial cells but not placenta
31. Upregulation of placental Ski-like proto-oncogene in preterm preeclampsia: potential target for preeclampsia treatment?
32. Characterising side population genes in placentas from patients with preeclampsia and/or fetal growth restriction.
33. In vitro investigation into the regulation and function of SPINT1, a biomarker for fetal growth restriction
34. The Brain Natriuretic Peptide (BNP) system is expressed in the placenta and vasculature in preeclampsia: potential implications for novel therapeutic strategies
35. Therapeutic intervention to alleviate long-term cardiovascular risk following preeclampsia
36. Screening circulating proteins to identify biomarkers of fetal macrosomia
37. The Regulation of Endothelin-1 in Pregnancies Complicated by Gestational Diabetes: Uncovering the Vascular Effects of Insulin.
38. A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin
39. Epidermal Growth Factor Rescues Endothelial Dysfunction in Primary Human Tissues In Vitro
40. Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin
41. Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta
42. Quantitative Point of Care Tests for Timely Diagnosis of Early‐Onset Preeclampsia with High Sensitivity and Specificity.
43. Circulating Chemerin Is Elevated in Women With Preeclampsia.
44. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks’ gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study
45. Circulating serine peptidase inhibitor Kunitz type 1 (SPINT1) in the second trimester is reduced among pregnancies that end in low birthweight neonates: cohort study of 2006 pregnancies
46. Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction
47. Investigating the Effects of Atrial Natriuretic Peptide on the Maternal Endothelium to Determine Potential Implications for Preeclampsia.
48. Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model.
49. Expression of Myostatin in Intrauterine Growth Restriction and Preeclampsia Complicated Pregnancies and Alterations to Cytokine Production by First-Trimester Placental Explants Following Myostatin Treatment
50. Chorioamnionitis Occurring in Women With Preterm Rupture of the Fetal Membranes Is Associated With a Dynamic Increase in mRNAs Coding Cytokines in the Maternal Circulation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.